{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:22:13Z","timestamp":1794007333936,"version":"4.8.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40121-025-01120-7","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:16:13Z","timestamp":1741698973000},"page":"889-895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["It\u2019s Here, It\u2019s There, There\u2019s Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1327-8313","authenticated-orcid":false,"given":"Jacob M.","family":"Keck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan K.","family":"Dare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell B.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Viteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Bradsher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"1120_CR1","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3390\/antibiotics11060718","volume":"11","author":"N Barantsevich","year":"2022","unstructured":"Barantsevich N, Barantsevich E. Diagnosis and treatment of invasive candidiasis. Antibiotics (Basel). 2022;11:718.","journal-title":"Antibiotics (Basel)"},{"key":"1120_CR2","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/jac\/dkad139","volume":"78","author":"A Soriano","year":"2023","unstructured":"Soriano A, Honore PM, Puerta-Alcalde P, et al. Invasive candidiasis: current clinical challenges and unmet needs in adult populations. J Antimicrob Chemother. 2023;78:1569\u201385.","journal-title":"J Antimicrob Chemother"},{"key":"1120_CR3","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/jac\/dkx444","volume":"73","author":"F Lamoth","year":"2018","unstructured":"Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73:i4\u201313.","journal-title":"J Antimicrob Chemother"},{"key":"1120_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-024-00503-3","volume":"10","author":"C Lass-Fl\u00f6rl","year":"2024","unstructured":"Lass-Fl\u00f6rl C, Kanj SS, Govender NP, Thompson GR, Ostrosky-Zeichner L, Govrins MA. Invasive candidiasis. Nat Rev Dis Primers. 2024;10:20.","journal-title":"Nat Rev Dis Primers"},{"key":"1120_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2015","unstructured":"Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2015;62:e1\u201350.","journal-title":"Clin Infect Dis"},{"key":"1120_CR6","doi-asserted-by":"publisher","first-page":"i14","DOI":"10.1093\/jac\/dkx445","volume":"73","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Righi E, Montravers P, Cornely OA. What has changed in the treatment of invasive candidiasis? A look at the past 10\u00a0years and ahead. J Antimicrob Chemother. 2018;73:i14\u201325.","journal-title":"J Antimicrob Chemother"},{"key":"1120_CR7","first-page":"485","volume":"20","author":"PG Pappas","year":"2006","unstructured":"Pappas PG. Invasive candidiasis. Infect Dis Clin. 2006;20:485\u2013506.","journal-title":"Infect Dis Clin"},{"key":"1120_CR8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/17460913.2024.2342150","volume":"19","author":"JD Paiva Macedo","year":"2024","unstructured":"Paiva Macedo JD, Dias VC. Antifungal resistance: why are we losing this battle? Futur Microbiol. 2024;19:1027\u201340.","journal-title":"Futur Microbiol"},{"key":"1120_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","volume":"20","author":"MC Fisher","year":"2022","unstructured":"Fisher MC, Alastruey-Izquierdo A, Berman J, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20:557\u201371.","journal-title":"Nat Rev Microbiol"},{"key":"1120_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40588-024-00219-8","volume":"11","author":"ST Hui","year":"2024","unstructured":"Hui ST, Gifford H, Rhodes J. Emerging antifungal resistance in fungal pathogens. Curr Clin Microbiol Rep. 2024;11:43\u201350.","journal-title":"Curr Clin Microbiol Rep"},{"key":"1120_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70160","volume":"7","author":"MA Rahman","year":"2024","unstructured":"Rahman MA, Victoros E, Shanjana Y, Thomas MR, Islam MR. The Candida auris infection after the COVID-19 pandemic seems to be an urgent public health emergency: a call to attention. Health Sci Rep. 2024;7:e70160.","journal-title":"Health Sci Rep"},{"key":"1120_CR12","doi-asserted-by":"publisher","first-page":"myae042","DOI":"10.1093\/mmy\/myae042","volume":"62","author":"HY Kim","year":"2024","unstructured":"Kim HY, Nguyen TA, Kidd S, et al. Candida auris\u2014a systematic review to inform the World Health Organization fungal priority pathogens list. Med Mycol. 2024;62:myae042.","journal-title":"Med Mycol"},{"key":"1120_CR13","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1080\/14656566.2021.1935868","volume":"22","author":"AG Stewart","year":"2021","unstructured":"Stewart AG, Paterson DL. How urgent is the need for new antifungals? Expert Opin Pharmacother. 2021;22:1857\u201370.","journal-title":"Expert Opin Pharmacother"},{"key":"1120_CR14","doi-asserted-by":"publisher","first-page":"foaa023","DOI":"10.1093\/femsyr\/foaa023","volume":"20","author":"D Li","year":"2020","unstructured":"Li D, She X, Calderone R. The antifungal pipeline: the need is established. Are there new compounds? FEMS Yeast Res. 2020;20:foaa023.","journal-title":"FEMS Yeast Res"},{"key":"1120_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/jof6040192","volume":"6","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Perlin DS. Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data. J Fungi (Basel). 2020;6:192.","journal-title":"J Fungi (Basel)"},{"key":"1120_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0140-6736(22)02371-6","volume":"401","author":"J Guinea","year":"2023","unstructured":"Guinea J. Rezafungin and invasive candida infections: a new game changing antifungal? Lancet. 2023;401:3\u20135.","journal-title":"Lancet"},{"key":"1120_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/fmb-2020-0217","volume":"16","author":"YY Ham","year":"2021","unstructured":"Ham YY, Lewis JS II, Thompson GR III. Rezafungin: a novel antifungal for the treatment of invasive candidiasis. Future Microbiol. 2021;16:27\u201336.","journal-title":"Future Microbiol"},{"key":"1120_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","volume":"401","author":"GR Thompson","year":"2023","unstructured":"Thompson GR, Soriano A, Cornely OA, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase\u00a03 trial. Lancet. 2023;401:49\u201359.","journal-title":"Lancet"},{"key":"1120_CR19","doi-asserted-by":"publisher","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","volume":"73","author":"GR Thompson","year":"2021","unstructured":"Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus caspofungin in a phase\u00a02, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis. 2021;73:e3647\u201355.","journal-title":"Clin Infect Dis"},{"key":"1120_CR20","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/microorganisms12050903","volume":"12","author":"G Viceconte","year":"2024","unstructured":"Viceconte G, Buonomo AR, Esposito N, et al. Salvage therapy with rezafungin for Candida parapsilosis spondylodiscitis: a case report from expanded access program. Microorganisms. 2024;12:903.","journal-title":"Microorganisms"},{"key":"1120_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00750-24","volume":"68","author":"G Ponta","year":"2024","unstructured":"Ponta G, Morena V, Strano M, et al. Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy). Antimicrob Agents Chemother. 2024;68:e0075024.","journal-title":"Antimicrob Agents Chemother"},{"key":"1120_CR22","doi-asserted-by":"publisher","first-page":"dlae042","DOI":"10.1093\/jacamr\/dlae042","volume":"6","author":"G Mori","year":"2024","unstructured":"Mori G, Gottardi M, Guffanti M, Castagna A, Lanzafame M. Treatment of Candida glabrata native valve endocarditis with rezafungin: a case report. JAC-Antimicrob Resist. 2024;6:dlae042.","journal-title":"JAC-Antimicrob Resist"},{"key":"1120_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5194\/jbji-9-213-2024","volume":"9","author":"M Lahouati","year":"2024","unstructured":"Lahouati M, Tin\u00e9vez C, Gabriel F, Xuereb F, Lefranc M, Dauchy FA. Efficacy of rezafungin in a case of Candida spondylodiskitis. J Bone Joint Infect. 2024;9:213\u20135.","journal-title":"J Bone Joint Infect"},{"key":"1120_CR24","doi-asserted-by":"publisher","first-page":"ofab431","DOI":"10.1093\/ofid\/ofab431","volume":"8","author":"A Adeel","year":"2021","unstructured":"Adeel A, Qu MD, Siddiqui E, Levitz SM, Ellison RT 3rd. Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: a case report. Open Forum Infect Dis. 2021;8:ofab431.","journal-title":"Open Forum Infect Dis"},{"key":"1120_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3201\/eid2605.191588","volume":"26","author":"K Arensman","year":"2020","unstructured":"Arensman K, Miller JL, Chiang A, et al. Clinical outcomes of patients treated for Candida auris infections in a multisite health system, Illinois, USA. Emerg Infect Dis. 2020;26:876\u201380.","journal-title":"Emerg Infect Dis"},{"key":"1120_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/antibiotics13070644","volume":"13","author":"A Dinh","year":"2024","unstructured":"Dinh A, B\u00e9raud G, Courjon J, et al. What place is there for long-acting antibiotics in the management of gram-positive infections? A qualitative cross-sectional study. Antibiotics. 2024;13:644.","journal-title":"Antibiotics"},{"key":"1120_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/phar.2389","volume":"40","author":"M Krsak","year":"2020","unstructured":"Krsak M, Morrisette T, Miller M, et al. Advantages of outpatient treatment with long-acting lipoglycopeptides for serious gram-positive infections: a review. Pharmacotheraphy. 2020;40:469\u201378.","journal-title":"Pharmacotheraphy"},{"key":"1120_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.02438-19","volume":"64","author":"M Helleberg","year":"2020","unstructured":"Helleberg M, J\u00f8rgensen KM, Hare RK, Datcu R, Chowdhary A, Arendrup MC. Rezafungin in vitro activity against contemporary Nordic clinical Candida isolates and Candida auris determined by the EUCAST reference method. Antimicrob Agents Chemother. 2020;64:10\u20131128.","journal-title":"Antimicrob Agents Chemother"},{"key":"1120_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/myc.70001","volume":"67","author":"ML Winkler","year":"2024","unstructured":"Winkler ML, Rhomberg P, Klauer AL, Edeker S, Castanheira M. The in vitro activity of rezafungin against uncommon species of Candida. Mycoses. 2024;67:e70001.","journal-title":"Mycoses"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01120-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T16:56:44Z","timestamp":1744477004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01120-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01120-7","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jacob Myles Keck is a consultant and speaker representative of AbbVie. Ryan Keith Dare has nothing to disclose. Mitchell Bruce Jenkins has nothing to disclose. Juan Carlos Rico has nothing to disclose. Luke Grisham has nothing to disclose. Jennifer McDonald has nothing to disclose. Alina Viteri has nothing to disclose. Robert Wilder Bradsher has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}